Oncoinvent ASA (OL:KLDVK) — Stock Price
Oncoinvent ASA (OL:KLDVK) is currently trading at Nkr5.00 NOK, down 2.91% today. Over the past 52 weeks, shares have ranged between Nkr3.20 and Nkr11.70. This page tracks Oncoinvent ASA's live share price on the OL exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see how efficiently does Oncoinvent ASA generate cash.
Oncoinvent ASA (KLDVK) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Oncoinvent ASA's daily closing share price and trading volume on the OL exchange over the past year, giving a clear view of recent price momentum and liquidity.
Oncoinvent ASA Income Statement — Revenue, Profit & Earnings by Year
Oncoinvent ASA's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | Nkr112.26 Million | Nkr102.16 Million | Nkr29.72 Million | Nkr56.64 Million | Nkr32.32 Million |
| Cost of Revenue | Nkr81.83 Million | Nkr67.92 Million | Nkr-8.81 Million | Nkr33.15 Million | Nkr16.65 Million |
| Gross Profit | Nkr30.43 Million | Nkr34.24 Million | Nkr38.53 Million | Nkr23.48 Million | Nkr15.67 Million |
| Research & Development | — | Nkr42.00K | Nkr0.00 | — | Nkr0.00 |
| SG&A | — | Nkr24.19 Million | Nkr17.59 Million | Nkr10.41 Million | Nkr284.15K |
| Total Operating Expenses | Nkr142.11 Million | Nkr121.82 Million | Nkr13.11 Million | Nkr58.89 Million | Nkr28.45 Million |
| Operating Income | Nkr-29.85 Million | Nkr-19.66 Million | Nkr16.61 Million | Nkr-2.25 Million | Nkr3.87 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | Nkr17.23 Million | Nkr13.80 Million | Nkr10.71 Million | Nkr5.81 Million | Nkr2.00 Million |
| Income Before Tax | Nkr-47.94 Million | Nkr-33.80 Million | Nkr6.56 Million | Nkr-7.23 Million | Nkr2.45 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | Nkr-48.10 Million | Nkr-30.61 Million | Nkr5.70 Million | Nkr-5.03 Million | Nkr2.00 Million |
Oncoinvent ASA Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Oncoinvent ASA's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | Nkr507.79 Million | Nkr482.47 Million | Nkr427.47 Million | Nkr311.53 Million | Nkr171.53 Million |
| Total Current Assets | Nkr151.90 Million | Nkr151.34 Million | Nkr124.93 Million | Nkr38.85 Million | Nkr44.34 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | Nkr6.57 Million | Nkr8.50 Million | Nkr3.31 Million | Nkr3.28 Million | Nkr1.25 Million |
| Inventory | Nkr132.68 Million | Nkr136.56 Million | Nkr116.50 Million | Nkr32.32 Million | Nkr39.13 Million |
| Property, Plant & Equipment | — | Nkr135.66 Million | Nkr117.11 Million | Nkr103.24 Million | — |
| Goodwill | — | Nkr20.20 Million | Nkr20.61 Million | Nkr17.96 Million | — |
| Total Liabilities | Nkr230.30 Million | Nkr214.71 Million | Nkr143.77 Million | Nkr119.51 Million | Nkr59.25 Million |
| Total Current Liabilities | Nkr27.96 Million | Nkr54.66 Million | Nkr28.67 Million | Nkr58.33 Million | Nkr16.88 Million |
| Long-term Debt | — | Nkr152.61 Million | Nkr102.75 Million | Nkr49.11 Million | Nkr38.38 Million |
| Net Debt | — | Nkr164.08 Million | Nkr109.86 Million | Nkr100.47 Million | Nkr46.15 Million |
| Total Stockholder Equity | Nkr277.49 Million | Nkr267.76 Million | Nkr283.70 Million | Nkr192.02 Million | Nkr112.26 Million |
| Retained Earnings | — | Nkr1.00K | Nkr169.00 | — | — |
Oncoinvent ASA Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Oncoinvent ASA generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | Nkr-23.24 Million | Nkr-14.84 Million | Nkr-40.23 Million | Nkr373.06K | Nkr130.66K |
| Capital Expenditures | Nkr14.77 Million | Nkr23.91 Million | Nkr19.44 Million | Nkr12.12 Million | Nkr30.88 Million |
| Free Cash Flow | Nkr-38.01 Million | Nkr-38.76 Million | Nkr-62.76 Million | Nkr-13.21 Million | Nkr-30.75 Million |
| Investing Cash Flow | — | Nkr-23.54 Million | Nkr-18.30 Million | Nkr-453.42K | — |
| Financing Cash Flow | — | Nkr39.76 Million | Nkr57.55 Million | Nkr1.57 Million | — |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | Nkr12.35 Million | Nkr11.09 Million | Nkr10.84 Million | Nkr7.74 Million | Nkr3.85 Million |
| Change in Cash | Nkr10.09 Million | Nkr1.38 Million | Nkr-1.06 Million | Nkr1.54 Million | Nkr-14.33 Million |
Oncoinvent ASA Earnings History — EPS Actual vs. Analyst Estimates
Track Oncoinvent ASA's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 21, 2026 | — | 0.59 | — |
| Feb 25, 2026 | -1.11 | 0.46 | -341.30% |
| Nov 21, 2025 | -0.81 | 0.00 | -40400.00% |
| Aug 28, 2025 | -0.77 | 0.14 | -650.00% |
| May 28, 2025 | 0.35 | 0.29 | +20.69% |
| Feb 26, 2025 | -2.10 | 0.12 | -1850.00% |
| Nov 20, 2024 | -0.18 | -0.19 | +5.26% |
| Aug 29, 2024 | -0.31 | -0.18 | -72.22% |